These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 34636915)
41. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. ; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017 [TBL] [Abstract][Full Text] [Related]
42. Effects of an Educational Program for Prostate Cancer Prevention on knowledge and PSA Testing in Men Over 50 Years old in Community Areas of Shiraz in 2016. Molazem Z; Ebadi M; Khademian M; Zare R Asian Pac J Cancer Prev; 2018 Mar; 19(3):633-637. PubMed ID: 29580031 [TBL] [Abstract][Full Text] [Related]
43. PSA Screening for Prostate Cancer: Why Saying No is a High-Value Health Care Choice. Wilt TJ; Dahm P J Natl Compr Canc Netw; 2015 Dec; 13(12):1566-74. PubMed ID: 26656523 [TBL] [Abstract][Full Text] [Related]
44. Supporting informed decision making online in 20 minutes: an observational web-log study of a PSA test decision aid. Joseph-Williams N; Evans R; Edwards A; Newcombe RG; Wright P; Grol R; Elwyn G J Med Internet Res; 2010 May; 12(2):e15. PubMed ID: 20507844 [TBL] [Abstract][Full Text] [Related]
45. Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish randomized study of screening for prostate cancer. Lindberg A; Talala K; Kujala P; Stenman UH; Taari K; Kilpeläinen TP; Tammela TL; Auvinen A Int J Cancer; 2019 Aug; 145(3):632-638. PubMed ID: 30653262 [TBL] [Abstract][Full Text] [Related]
46. Pre-screening Discussions and Prostate-Specific Antigen Testing for Prostate Cancer Screening. Li J; Zhao G; Hall IJ Am J Prev Med; 2015 Aug; 49(2):259-63. PubMed ID: 25997905 [TBL] [Abstract][Full Text] [Related]
47. Informed decision making and prostate specific antigen (PSA) testing for prostate cancer: a randomised controlled trial exploring the impact of a brief patient decision aid on men's knowledge, attitudes and intention to be tested. Watson E; Hewitson P; Brett J; Bukach C; Evans R; Edwards A; Elwyn G; Cargill A; Austoker J Patient Educ Couns; 2006 Nov; 63(3):367-79. PubMed ID: 16875796 [TBL] [Abstract][Full Text] [Related]
48. A Randomized Controlled Effectiveness Trial for PSA Screening Decision Support Interventions in Two Primary Care Settings. Lewis CL; Adams J; Tai-Seale M; Huang Q; Knowles SB; Nielsen ME; Pignone MP; Walter LC; Frosch DL J Gen Intern Med; 2015 Jun; 30(6):810-6. PubMed ID: 25666221 [TBL] [Abstract][Full Text] [Related]
49. Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis. Martin AJ; Lord SJ; Verry HE; Stockler MR; Emery JD Med J Aust; 2013 Jun; 198(10):546-50. PubMed ID: 23725269 [TBL] [Abstract][Full Text] [Related]
50. Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer. Roobol MJ; Kranse R; Bangma CH; van Leenders AG; Blijenberg BG; van Schaik RH; Kirkels WJ; Otto SJ; van der Kwast TH; de Koning HJ; Schröder FH; Eur Urol; 2013 Oct; 64(4):530-9. PubMed ID: 23759326 [TBL] [Abstract][Full Text] [Related]
51. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. Hayes JH; Barry MJ JAMA; 2014 Mar; 311(11):1143-9. PubMed ID: 24643604 [TBL] [Abstract][Full Text] [Related]
52. Men's view on participation in decisions about prostate-specific antigen (PSA) screening: patient and public involvement in development of a survey. Birkeland S; Pedersen SS; Haakonsson AK; Barry MJ; Rottmann N BMC Med Inform Decis Mak; 2020 Apr; 20(1):65. PubMed ID: 32252729 [TBL] [Abstract][Full Text] [Related]
53. Comparing perceived clarity of information on overdiagnosis used for breast and prostate cancer screening in England: an experimental survey. Ghanouni A; Renzi C; McBride E; Waller J BMJ Open; 2017 Aug; 7(8):e015955. PubMed ID: 28827249 [TBL] [Abstract][Full Text] [Related]
54. Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy. Avery KN; Metcalfe C; Vedhara K; Lane JA; Davis M; Neal DE; Hamdy FC; Donovan JL; Blazeby JM Eur Urol; 2012 Oct; 62(4):649-55. PubMed ID: 22244151 [TBL] [Abstract][Full Text] [Related]
55. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening. Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Chun FK; Recker F; Kwiatkowski M Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075 [TBL] [Abstract][Full Text] [Related]
56. A Web-Based Decision Aid for Informed Prostate Cancer Screening: Development and Pilot Evaluation. Jung W; Cho IY; Jeon KH; Yeo Y; Jun JK; Suh M; Jeong A; Lee J; Shin DW J Korean Med Sci; 2023 Nov; 38(46):e360. PubMed ID: 38013645 [TBL] [Abstract][Full Text] [Related]
57. Resisting recommended treatment for prostate cancer: a qualitative analysis of the lived experience of possible overdiagnosis. McCaffery K; Nickel B; Pickles K; Moynihan R; Kramer B; Barratt A; Hersch J BMJ Open; 2019 May; 9(5):e026960. PubMed ID: 31122983 [TBL] [Abstract][Full Text] [Related]
58. National evidence on the use of shared decision making in prostate-specific antigen screening. Han PK; Kobrin S; Breen N; Joseph DA; Li J; Frosch DL; Klabunde CN Ann Fam Med; 2013; 11(4):306-14. PubMed ID: 23835816 [TBL] [Abstract][Full Text] [Related]
59. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden. Vickers AJ; Cronin AM; Aus G; Pihl CG; Becker C; Pettersson K; Scardino PT; Hugosson J; Lilja H Cancer; 2010 Jun; 116(11):2612-20. PubMed ID: 20336781 [TBL] [Abstract][Full Text] [Related]
60. Health literacy and shared decision making for prostate cancer patients with low socioeconomic status. Kim SP; Knight SJ; Tomori C; Colella KM; Schoor RA; Shih L; Kuzel TM; Nadler RB; Bennett CL Cancer Invest; 2001; 19(7):684-91. PubMed ID: 11577809 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]